Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Osaka Prefecture Asking Korosho to Provide Pharmaceutical Strategy Consultation Services in Kansai Region
February 16, 2012
- Over 30 Companies Target Nu-lotan Generic Listing in June, 60% Pricing Rule to Apply
February 15, 2012
- Prof. Matsumoto of OPMI Stresses Need to Enhance Competitiveness of Pharmaceutical Industry
February 14, 2012
- MHLW Postpones Ban of Dispensing Points to October
February 14, 2012
- PAFSC’s First Committee on Drugs to Review Astellas’ Hyperphosphatemia Treatment on February 24
February 14, 2012
- Healthcare Providers, Bill Payers in Face-Off Over Additional Premiums for Generic Name Prescriptions
February 13, 2012
- CSIMC’S Medical Fee Reform Plan for FY2012 to Promote Faster Patient Discharge, Functional Specialization
February 13, 2012
- FY2012 Medical Fee Revision to Include New Measures to Promote Generic Drug Use
February 13, 2012
- Guidance Fee for Psychiatric Patients to Be Reduced from 55 to 44 Points When Prescribing 3 or More Drugs
February 10, 2012
- Delivery Price Settlement Rate Just 79.1% at End of December: MHLW
February 9, 2012
- Selection Process for Clinical Research Core Hospitals to Begin in Early March
February 9, 2012
- US FDA Warns against Risk of CDAD in Patients Taking PPIs
February 9, 2012
- Drug Discovery Support Organization Needed to Prevent “Decay” of Drug Industry: Mr Hachiyama
February 8, 2012
- Prime Minister Noda Asks Korosho to Study Simultaneous Revisions of Medical, Nursing Fees Every 3 Years
February 7, 2012
- Japan’s Cancer Registry System Lags Behind Other Developed Countries: Mr Umemura of DPJ
February 7, 2012
- Growing Concerns that Premium for New Drug Development May Violate Antimonopoly Act
February 6, 2012
- National, Rosai Hospitals to Enhance Relationship Aiming at Joint Purchasing in July
February 3, 2012
- MHLW to Strengthen Counterfeit Drug Control Creating Public-Private Council
February 3, 2012
- PAFSC's 2nd Committee on Drugs Recommends Approval for Kyowa Kirin's ATL Treatment
February 2, 2012
- Application Based on Data from Public Domain Recommended for Baktar, Flagyl: PAFSC Second Committee
February 2, 2012
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…